To access all features of this site, you must enable Javascript. Here are the instructions for enabling Javascript in your web browser.
The François Jacob Institute of Biology brings together five departments and three services
The last two years in scientific news
In a study published in Nature Communications, IDMIT researchers demonstrated the efficacy of a neutralizing antibody against cell-associated infection by simian-human immunodeficiency virus.
Using a murine preclinical model wherein Rad51 was selectively inhibited, researchers from the Laboratory of Development of the Gonads (iRCM:CEA-Jacob) and the Institut Cochin showed that in vivo alteration of Rad51-mediated homologous recombination does not favor the development of cancers, it reduces it. The team's work was published in The Embo Journal.
In an article published in Nature Communications, researchers from Institut Jacques-Monod and iRCM (CEA-Jacob) merged imaging and biochemistry approaches to show that the genes involved in expression are conducted to nuclear pores in order to protect the genome.
In an article published in Science of The Total Environment, researchers from the Genomics Metabolics mixed research unit (Genoscope/CEA-Jacob) teamed with colleagues from the University of Lorraine to demonstrate the role of thermophilic anaerobic digestion in the biodegradation of chlordecone.
In a new study published in Nature Communications, researchers from IDMIT and the QIMR Berghofer Institute have shown that a peptide able to inhibit the nuclear ACE2 receptor provides protection against SARS-CoV-2 infection.
In a study published in Heliyon, researchers from IDMIT (CEA-Jacob) used a well-characterized non-human primate model to show that sotrovimab is efficacious against the BQ.1.1 subvariant of SARS-CoV-2. Their results lend support for the continued use of sotrovimab in patients ineligible for nirmatrelvir/ritonavir.
In a new study performed in a mouse model and published in Acta Neuropathologica Communications, researchers from the LMN (MIRCen/CEA-Jacob) have shown that the experimental transmission of abnormal amyloid-β proteins accelerates, over time, the development of cerebral lesions and memory disorders.
Carole Escartin's Reactive Astrocytes team (UMR9199, Neurodegenerative Diseases Laboratory, MIRCen) has received the Équipe FRM 2023 label for its project on the role of astrocytes in the control of neuronal activity.
Launched in December 2022, the European project BlueRemediomics aims to valorize currently unexploited marine microbial resources. The four-year project brings together an international consortium of experts, including the Genomics Metabolics mixed research unit (Genoscope/CEA-Jacob), and enables the development of novel tools and approaches to explore marine microbiome data.
The CEA is coordinating the European COUNTERACT project aimed at better preparing the European Union for chemical, biological, radiological and nuclear (CBRN) threats.
The project CHLOR2NOU, coordinated by Genoscope (CEA-Jacob), was chosen as a laureate of the first chlordecone joint research call for proposals. The project is aimed at developing novel tools for the surveillance of chlordecone and its transformation products.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.